Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study

Digestive and Liver Disease

Volumn 44, Issue 5, 2012, Pages 406-412

  Giordanino, Chiara ^a   Ceretto, Simone ^a   Bo, Simona ^b   Smedile, Antonina ^b   Ciancio, Alessia ^b   Bugianesi, Elisabetta ^b   Pellicano, Rinaldo ^b   Fagoonee, Sharmila ^a   Versino, Elisabetta ^c   Costa, Giuseppe ^c   Arese, Daniele ^a   Sacco, Marco ^a   Rizzetto, Mario ^b   Saracco, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c San Luigi Medical School   (Italy)

Author keywords

Chronic hepatitis C; Diabetes mellitus; Hepatitis C Virus; Impaired fasting glucose; Interferon; Ribavirin

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HEART INFARCTION; HEPATITIS C; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

BODY MASS INDEX; COHORT STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION; ITALY; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84859213032     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.12.003     Document Type: Article

References (42)

1. Eslam M., Khattab M., Harrison S.A. Insulin resistance and hepatitis C: an evolving story. Gut 2011, 60:1139-1151.
2. Ratziu V., Munteanu M., Charlotte F., et al. Fibrogenic impact of high serous glucose in chronic hepatitis C. J Hepatol 2003, 39:1049-1055.
3. Hickman I.J., Powell E.E., Prins J.B., et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003, 39:1042-1048.
4. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003, 125:1695-1704.
5. Muzzi A., Leandro G., Rubbia-Brandt L., et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005, 42:41-46.
6. Bugianesi E., Marchesini G., Gentilcore E., et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006, 44:1648-1655.
7. Kita Y., Mizukoshi E., Takamura T., et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism 2007, 56:1682-1688.
8. Cua I.H., Hui J.M., Kench J.G., et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008, 48:723-731.
9. Huang J.F., Yu M.L., Dai C.Y., et al. Pretreatment insulin sensitivity contributes to the treatment response to peginterferon plus ribavirin combination therapy for patients with chronic hepatitis C. Hepatology 2007, 46:349A.
10. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
11. D'Souza R., Sabin C.A., Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005, 100:1509-1515.
12. Persico M., Capasso M., Persico E., Svelto M., et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007, 46:1009-1015.
13. Poustchi H., Negro F., Hui J., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008, 48:28-34.
14. Chu C.J., Lee S.D., Hung T.H., et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009, 29:46-54.
15. Lai M.S., Hsieh M.S., Chiu Y.H., et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis visur infection. Hepatology 2006, 43:1295-1302.
16. Tazawa J., Maeda M., Nakagawa M., et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002, 47:710-715.
17. Veldt B.J., Chen W., Heathcote, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
18. Donadon V., Balbi M., Zanette G. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and type 2 diabetes mellitus. Expert Rev Gastroenterol Hepatol 2009, 3:465-467.
19. Negro F., Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009, 15:1537-1547.
20. Simò R., Lecube A., Genescà J., et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006, 29:2462-2466.
21. Romero-Gomez M., Fernandez-Rodriguez C.M., Andrade R.J., et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008, 48:721-727.
22. Arase Y., Suzuki F., Suzuki Y., Akuta, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009, 49:739-744.
23. Giordanino C., Bugianesi E., Smedile A., et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol 2008, 103:2481-2487.
24. Bo S., Cavallo Perin P., Gentile L., et al. Influence of a familial history of diabetes on the clinical characteristics of patients with type 2 diabetes mellitus. Diabet Med 2000, 17:538-542.
25. Bruno G., Bargero G., Vuolo A., et al. A population-based prevalence survey of known diabetes mellitus in Northern Italy based upon multiple independent sources of ascertainment. Diabetologia 1992, 35:851-856.
26. Joint National Committee The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1993, 153:154-183.
27. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28(Suppl. 1):S37-S42.
28. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005, 366:1059-1062. IDF Epidemiology Task Force Consensus Group.
29. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
30. Kettaneh A., Marcellin P., Douvin C., et al. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients. A prospective study of 935 patients. J Hepatol 2007, 46:628-634.
31. Hung C.H., Lee C.M., Wang J.H., et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer 2011, 128:2344-2352.
32. Mehta S.H., Brancati F.L., Strathdee S.A., et al. Hepatitis C Virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
33. Henriksen J.H., Moller S. Liver cirrhosis and arterial hypertension. World J Gastroenterol 2006, 12:678-685.
34. Kalaitzakis E., Rosengren A., Skommevik T., et al. Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci 2010, 55:467-475.
35. Marchesini G., Ronchi M., Forlani G., et al. Cardiovascular disease in cirrhosis: a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999, 94:655-662.
36. Fujiwara F., Ishii M., Taneichi H., et al. Low incidence of vascular complications in patients with diabetes mellitus associated with liver cirrhosis as compared with type 2 diabetes mellitus. Tohoku J Exp Med 2005, 205:327-334.
37. Holstein A., Hinze S., Thiessen E., et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002, 17:677-681.
38. Tamura M., Kihara Y., Otsuki M. Carotid intima-media thickness in patients with liver cirrhosis associated with diabetes mellitus. Diabetes Res Clin Pract 2007, 78:176-181.
39. Melato M., Mucli E., Poldrugo F., et al. Stroke-cirrhosis relationship: an autopsy study in a heavy drinking population. Ital J Gastroenterol 1991, 23:211-214.
40. Berzigotti A., Bonfiglioli A., Muscari A., et al. Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int 2005, 25:331-336.
41. D'Arienzo A., Manguso F., Scaglione G., et al. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 1998, 33:1213-1218.
42. Donadon V., Balbi M., Valent F., et al. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010, 16:3025-3032.